The National Institute for Health and Care Excellence (NICE) will be consulting on the safety and efficacy of platelet-rich plasma injections for osteoarthritis of the knee as part of its Interventional Procedures Programme (IPP). Public consultation is for four weeks and runs between 23 August 2018 and 5pm 20 September 2018.
NICE would be pleased to receive any comments that you may have on provisional recommendations and information on recently published literature not included in the procedure overview.
If you would like to comment then please do so via the NICE website.
Musculoskeletal conditions are common – we all know that. But it hadn’t struck me until recently just how common compared to other long term conditions. 17 million people in the UK have an MSK condition. Compare that with the 850,000 with dementia and think about how much we talk about dementia. It’s a similar picture for other conditions: diabetes, 3.5 million people, cardiovascular, 7 million. Only mental health exceeds the prevalence of MSK conditions.
The National Institute for Health and Care Excellence (NICE) produces guidance on the most effective ways to prevent, diagnose and treat disease and ill health, and provide social care support. Their guidance is based on research evidence and takes into account the views of people working in or using relevant services, and other stakeholder groups.
Guest blog by Ms. Nuzhat Ali, National MSK Lead, Public Health England
